Inonotsuoxide B suppresses hepatic stellate cell activation and proliferation via the PI3K/AKT and ERK1/2 pathway

  • Authors:
    • Juan Jin
    • Hui Yang
    • Lili Hu
    • Yinghong Wang
    • Wenyong Wu
    • Chengmu Hu
    • Kun Wu
    • Zehua Wu
    • Wenming Cheng
    • Yan Huang
  • View Affiliations

  • Published online on: April 28, 2022     https://doi.org/10.3892/etm.2022.11344
  • Article Number: 417
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Hepatic stellate cells (HSCs) serve a pivotal role in the formation and degradation of the extracellular matrix during liver fibrosis. Inonotsuoxide B is a tetracyclic triterpenoid that can be extracted from Inonotus obliquus and has been previously reported to inhibit the growth of liver and gastric cancer cells. However, its effect on liver fibrosis remain poorly understood. Therefore, in the present study, the potential antiproliferative effects of inonotsuoxide B on HSCs was investigated. Initially, cells were divided into the following five groups: Control; platelet‑derived growth factor (PDGF)‑BB (10 ng/ml); and PDGF‑BB + inonotsuoxide B (5, 10 and 20 µg/ml) groups. Inonotsuoxide B treatment (5, 10 and 20 µg/ml) was revealed to reverse PDGF‑BB‑induced HSC proliferation. Furthermore, the protein expression of α‑smooth‑muscle actin (α‑SMA) and type I collagen was significantly decreased in the inonotsuoxide B (10 and 20 µg/ml) groups compared with the PDGF‑BB group. Inonotsuoxide B (5, 10 and 20 µg/ml) was also revealed to suppress PDGF‑BB‑induced α‑SMA mRNA expression and activation of the PI3K/AKT and ERK signaling pathways in HSCs. These findings suggest that inonotsuoxide B suppresses the proliferation and activation of HSCs by inhibiting the PI3K/AKT and ERK1/2 signaling pathways.
View Figures
View References

Related Articles

Journal Cover

June-2022
Volume 23 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Jin J, Yang H, Hu L, Wang Y, Wu W, Hu C, Wu K, Wu Z, Cheng W, Huang Y, Huang Y, et al: Inonotsuoxide B suppresses hepatic stellate cell activation and proliferation via the PI3K/AKT and ERK1/2 pathway. Exp Ther Med 23: 417, 2022.
APA
Jin, J., Yang, H., Hu, L., Wang, Y., Wu, W., Hu, C. ... Huang, Y. (2022). Inonotsuoxide B suppresses hepatic stellate cell activation and proliferation via the PI3K/AKT and ERK1/2 pathway. Experimental and Therapeutic Medicine, 23, 417. https://doi.org/10.3892/etm.2022.11344
MLA
Jin, J., Yang, H., Hu, L., Wang, Y., Wu, W., Hu, C., Wu, K., Wu, Z., Cheng, W., Huang, Y."Inonotsuoxide B suppresses hepatic stellate cell activation and proliferation via the PI3K/AKT and ERK1/2 pathway". Experimental and Therapeutic Medicine 23.6 (2022): 417.
Chicago
Jin, J., Yang, H., Hu, L., Wang, Y., Wu, W., Hu, C., Wu, K., Wu, Z., Cheng, W., Huang, Y."Inonotsuoxide B suppresses hepatic stellate cell activation and proliferation via the PI3K/AKT and ERK1/2 pathway". Experimental and Therapeutic Medicine 23, no. 6 (2022): 417. https://doi.org/10.3892/etm.2022.11344